Mechanisms of Efficacy of the PAN-FGFR Inhibitor AZD4547 in Pediatric Solid Tumor Models

被引：0
|
作者：
Zage, P. [1 ]
Hakim, S. [1 ]
Subramonian, D. [1 ]
Lesperance, J. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, Pediat, San Diego, CA 92103 USA
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-052
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 50 条
  • [41] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    Papadopoulos, K. P.
    El-Rayes, B. F.
    Tolcher, A. W.
    Patnaik, A.
    Rasco, D. W.
    Harvey, R. D.
    LoRusso, P. M.
    Sachdev, J. C.
    Abbadessa, G.
    Savage, R. E.
    Hall, T.
    Schwartz, B.
    Wang, Y.
    Kazakin, J.
    Shaib, W. L.
    BRITISH JOURNAL OF CANCER, 2017, 117 (11) : 1592 - 1599
  • [42] A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer
    Arkenau, Hendrik-Tobias
    Saggese, Matilde
    Hollebecque, Antoine
    Mathewson, Alastair
    Lemech, Charlotte Rose
    Landers, Donal
    Frewer, Paul
    Kilgour, Elaine
    Brooks, Nigel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    K P Papadopoulos
    B F El-Rayes
    A W Tolcher
    A Patnaik
    D W Rasco
    R D Harvey
    P M LoRusso
    J C Sachdev
    G Abbadessa
    R E Savage
    T Hall
    B Schwartz
    Y Wang
    J Kazakin
    W L Shaib
    British Journal of Cancer, 2017, 117 : 1592 - 1599
  • [44] Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
    Gozgit, Joseph M.
    Wong, Matthew J.
    Moran, Lauren
    Wardwell, Scott
    Mohemmad, Qurish K.
    Narasimhan, Narayana I.
    Shakespeare, William C.
    Wang, Frank
    Clackson, Tim
    Rivera, Victor M.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 690 - 699
  • [45] A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
    Jinho Kang
    Yoon Ji Choi
    Bo Yeon Seo
    Ukhyun Jo
    Serk In Park
    Yeul Hong Kim
    Kyong Hwa Park
    Scientific Reports, 9
  • [46] A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
    Kang, Jinho
    Choi, Yoon Ji
    Seo, Bo Yeon
    Jo, Ukhyun
    Park, Serk In
    Kim, Yeul Hong
    Park, Kyong Hwa
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [47] Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
    Hideo Saka
    Chiyoe Kitagawa
    Yoshihito Kogure
    Yasuo Takahashi
    Koshi Fujikawa
    Tamotsu Sagawa
    Satoru Iwasa
    Naoki Takahashi
    Taro Fukao
    Catherine Tchinou
    Dónal Landers
    Yasuhide Yamada
    Investigational New Drugs, 2017, 35 : 451 - 462
  • [48] Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
    Schuler, M.
    Nogova, L.
    Heidenreich, A.
    Tai, D.
    Cassier, P.
    Richly, H.
    Cho, B. C.
    Sayehli, C. M.
    Navarro, A.
    Bender, S.
    Ocker, M.
    Nogai, H.
    Wagner, A.
    Ince, S.
    Ellinghaus, P.
    Joerger, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
    Saka, Hideo
    Kitagawa, Chiyoe
    Kogure, Yoshihito
    Takahashi, Yasuo
    Fujikawa, Koshi
    Sagawa, Tamotsu
    Iwasa, Satoru
    Takahashi, Naoki
    Fukao, Taro
    Tchinou, Catherine
    Landers, Donal
    Yamada, Yasuhide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 451 - 462
  • [50] Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models
    Jerchel, Isabel S.
    Lejeune, Pascale
    Lampignano, Rita
    Walter, Alexander
    Lesche, Ralf
    Kamburov, Atanas
    Mumberg, Dominik
    Ellinghaus, Peter
    Politz, Oliver
    Gruenewald, Sylvia
    CANCER RESEARCH, 2019, 79 (13)
12345